地塞米鬆緩釋顆粒在糖尿病性白内障手術中的應用

目的 研究Tenon’s囊下植入地塞米松缓释颗粒控制糖尿病性白内障术后前房炎症反应的有效性和安全性。方法双眼糖尿病性白内障患者37例(74眼),一眼仅于白内障术毕Tenon’s囊下植入地塞米松缓释颗粒,术后不再使用激素性眼液,作为实验组;另一眼不植入地塞米松缓释颗粒,术后常规滴典必舒眼液,作为对照组。分别观察术后1、3、7、15天的前房炎症反应、睫状充血、眼压、角膜上皮、伤口愈合状况及血糖水平等指标。结果 术后1、15天时,两组的前房炎症反应无显著性差异;术后3、7天,实验组较对照组前房炎症反应轻(P<0.05);术后1、3、7、15天,两组睫状充血评分无显著差异;两组术后各天眼压无显著性差异;地塞米松缓释颗粒对血糖、角膜上皮及伤口愈合状况无明显影响。结论 对合并糖尿病的白内障患者,术毕Tenon’s囊下植入地塞米松缓释颗粒是一种安全有效的控制术后前房炎症反应的方式。

Application of dexamethasone sustained release granules (Surodex) in diabetic cataract surgery

Objective To study the safety and effectiveness of an sub-Tenon' s capsule dexamethasone sustained release microcapsules (Surodex) in treatment of anterior chamber inflammation following cataract surgery in diabetes. Methods 74 eyes of 37 diabetic patients with bilateral cataract were randomly classified into a treatment group or a control group to form a self-control. All 37 eyes in the treatment group received a Surodex sub-Tennon' s capsule when cataract surgery was being finished. 37 eyes of the control group were given only TobraDex eyedrops, not given Surodex. The scores of inflammation in anterior chamber, ciliary congestion, intraocular pressure, the state of corneal epithelia, healing of the wound and blood glucose were evaluated at 1,3, 7, 15 days after surgery respectively. Results No significance existed in the scores of inflammation in anterior chamber 1 day and 15 days after surgery between the two groups. But inflammation in the Surodex treatment group was slighter than that in the control group 3 and 7 days after surgery (P<0. 05). There was no significant difference in scores of ciliary congestion 1,3, 7, 15 days after surgery between the two groups. The difference was not significant in postoperative intraocular pressure. There was no difference in blood glucose, corneal epithelia and wound healing betweet the 2 groups. Conclusion In diabetic patients, Surodexg is safe and effective in suppressing inflammation following cataract surgery.